{"id":9556,"date":"2025-02-12T14:32:55","date_gmt":"2025-02-12T09:02:55","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=9556"},"modified":"2025-02-12T14:39:36","modified_gmt":"2025-02-12T09:09:36","slug":"alzheimers-disease-market","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market","title":{"rendered":"Can Remternetug Solve the Puzzle of Alzheimer\u2019s?"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69d2a5ced309f\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69d2a5ced309f\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market\/#Remternetug_A_Journey_Through_Clinical_Development\" >Remternetug: A Journey Through Clinical Development<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market\/#Remternetug_Clinical_Trials_The_Initial_Phase\" >Remternetug Clinical Trials: The Initial Phase<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market\/#Advancement_to_Phase_III_Trials\" >Advancement to Phase III Trials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market\/#Recent_Developments\" >Recent Developments<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market\/#Efficacy_and_Safety_Profile\" >Efficacy and Safety Profile<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market\/#Alzheimers_Disease_Current_Market_Scenario\" >Alzheimer\u2019s Disease Current Market Scenario<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market\/#How_Remternetug_Stands_Out_in_the_Current_Alzheimers_Therapeutic_Landscape\" >How Remternetug Stands Out in the Current Alzheimer\u2019s Therapeutic Landscape<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market\/#The_Future_of_Alzheimers_Treatment_A_Step_Closer_to_a_Breakthrough\" >The Future of Alzheimer\u2019s Treatment: A Step Closer to a Breakthrough<\/a><\/li><\/ul><\/nav><\/div>\n\n<p><strong>Alzheimer\u2019s disease <\/strong>has become one of the most pressing global health challenges, with its prevalence rising dramatically over the past few years. As the aging population grows, so does the burden of this neurodegenerative disorder, placing immense strain on healthcare systems worldwide. The <a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-market\" class=\"ek-link\"><strong>Alzheimer&#8217;s drug market<\/strong><\/a> has expanded significantly, driven by the urgent need for effective treatments to slow disease progression and improve patient outcomes.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"236\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/12133353\/Alzheimers-Disease-Market-Insights-2023-1024x236.png\" alt=\"Alzheimer's-Disease-Market-Insights-(2023)\" class=\"wp-image-31026\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/12133353\/Alzheimers-Disease-Market-Insights-2023-1024x236.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/12133353\/Alzheimers-Disease-Market-Insights-2023-300x69.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/12133353\/Alzheimers-Disease-Market-Insights-2023-150x35.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/12133353\/Alzheimers-Disease-Market-Insights-2023-768x177.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/12133353\/Alzheimers-Disease-Market-Insights-2023-1536x353.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/04\/12133353\/Alzheimers-Disease-Market-Insights-2023-2048x471.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>Currently, the <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-pipeline-insight\" class=\"ek-link\">Alzheimer&#8217;s disease treatment landscape<\/a><\/strong> is seeing a surge in approved therapies, with <strong>LEQEMBI <\/strong>making notable strides. From <strong>October to December 2024, <\/strong>LEQEMBI generated approximately $87.4 million, further establishing its presence in the market. Other than that, pharmaceutical companies are racing to develop groundbreaking therapies, with numerous clinical trials underway. From monoclonal antibodies targeting amyloid plaques to novel mechanisms addressing tau pathology, every contender in the space aims to crack the code of this devastating disease. Among the most <strong><em>promising candidates is <a href=\"https:\/\/www.delveinsight.com\/report-store\/remternetug-market-size-forecast-and-emerging-insight\">Remternetug<\/a>,<\/em> <\/strong>a <strong>late-phase III <\/strong>investigational therapy that has garnered significant attention for its potential to redefine Alzheimer\u2019s treatment. <em>Could this drug be the breakthrough the world has been waiting for?<\/em><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-remternetug-a-journey-through-clinical-development\"><span class=\"ez-toc-section\" id=\"Remternetug_A_Journey_Through_Clinical_Development\"><\/span>Remternetug: A Journey Through Clinical Development<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Remternetug,<\/strong> previously known as <strong>LY3372993<\/strong>, is an investigational monoclonal antibody developed by <strong>Eli Lilly and Company.<\/strong> Designed to target pyroglutamated amyloid-beta (A\u03b2), a key component of amyloid plaques in <strong>Alzheimer\u2019s disease<\/strong>, Remternetug follows a similar mechanism to donanemab, Lilly\u2019s FDA-approved antibody. A series of clinical trials have marked its development focused on assessing its safety, efficacy, and potential to modify the course of Alzheimer&#8217;s disease. As research advances, remternetug FDA approval\u200b stands as a promising contender in the race to combat this devastating neurodegenerative disease.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-remternetug-clinical-trials-the-initial-phase\"><span class=\"ez-toc-section\" id=\"Remternetug_Clinical_Trials_The_Initial_Phase\"><\/span>Remternetug Clinical Trials: The Initial Phase<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>In <strong>November 2018, Eli Lilly<\/strong> initiated a <strong>Phase I trial<\/strong> to compare remternetug to placebo in <strong>100 healthy adults<\/strong> and <strong>individuals <\/strong>with <strong>mild cognitive impairment (MCI) <\/strong>due to <strong>Alzheimer&#8217;s disease <\/strong>or <strong>mild <\/strong>to <strong>moderate Alzheimer&#8217;s disease. <\/strong>Participants received intravenous infusions of single or multiple escalating doses, with assessments focusing on adverse events, blood exposure levels, and the drug&#8217;s impact on brain amyloid as measured by florbetapir PET scans. However, in<strong> April 2019<\/strong>, after enrolling 36 healthy adults, the trial was terminated without enrolling any Alzheimer&#8217;s disease patients, and the results were not publicly disclosed.<\/p>\n\n\n\n<p>In<strong> July 2020,<\/strong> a new <strong>Phase I study commenced,<\/strong> enrolling <strong>30 participants<\/strong> with clinically diagnosed MCI due to Alzheimer&#8217;s disease or Alzheimer&#8217;s disease dementia. They received multiple escalating doses of remternetug or placebo over nine months. The primary outcome was the number of serious adverse events, while secondary outcomes included pharmacokinetics and changes in brain amyloid levels from baseline to week 25. <strong>In 2021,<\/strong> the study expanded to include 32 healthy adults of first-generation Japanese origin receiving a single infusion. Enrollment was later increased to 224 participants, the treatment period was extended to 61 weeks, and subcutaneous dosing was added. This trial was conducted at multiple U.S. and Japan sites, with completion in<strong> November 2024.<\/strong><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-advancement-to-phase-iii-trials\"><span class=\"ez-toc-section\" id=\"Advancement_to_Phase_III_Trials\"><\/span>Advancement to Phase III Trials<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>In <strong>August 2022,<\/strong> Eli Lilly initiated the <strong>Phase III TRAILRUNNER-ALZ1 trial<\/strong> to evaluate <strong>Remternetug<\/strong> as a potential breakthrough in the <a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-pipeline-insight\"><strong>Alzheimer\u2019s disease treatment<\/strong><\/a> landscape. The study initially aimed to randomize 400 individuals with <strong>early symptomatic Alzheimer\u2019s disease <\/strong>to receive <strong>Remternetug<\/strong> or placebo for one year, administered either intravenously or subcutaneously. The primary outcome focuses on <strong>amyloid plaque clearance<\/strong>, a critical target in <strong>Alzheimer\u2019s disease therapies<\/strong>, while secondary outcomes assess pharmacokinetics and the presence of anti-drug antibodies.<\/p>\n\n\n\n<p>As the <strong>Alzheimer\u2019s disease drug market<\/strong> continues to evolve, the trial expanded in 2023, increasing enrollment to 600 in the placebo-controlled arm and 974 in the safety cohort, adding additional sites in the U.S. and Japan. A blinded extension phase allows <strong>Remternetug<\/strong> recipients to switch to placebo and vice versa, ensuring a comprehensive assessment of long-term effects. The <strong>blinded portion<\/strong> of the study concluded in June 2024, with overall completion expected in March 2026, marking a significant step forward in advancing <strong>Alzheimer\u2019s disease therapies<\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-recent-developments\"><span class=\"ez-toc-section\" id=\"Recent_Developments\"><\/span>Recent Developments<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>In <strong>October 2024<\/strong>, the <strong>Phase III TRAILRUNNER-ALZ3 study<\/strong> was initiated to evaluate <strong>Remternetug<\/strong> as a potential breakthrough in the <strong>Alzheimer\u2019s disease treatment<\/strong> landscape. The trial aims to enroll <strong>1,200 participants<\/strong> with <strong>early Alzheimer\u2019s disease<\/strong>, administering <strong>subcutaneous injections<\/strong> of <strong>Remternetug<\/strong> or placebo over <strong>18 months<\/strong>, followed by a <strong>blinded observation period<\/strong>. The primary endpoint focuses on <strong>time to progression<\/strong> on the <strong>Clinical Dementia Rating (CDR) scale<\/strong>, a key measure in assessing disease advancement. Secondary outcomes include <strong>cognitive, behavioral, and functional assessments<\/strong>, along with <strong>serum antibody concentrations<\/strong> and <strong>adverse event monitoring<\/strong>, critical for evaluating <strong>Alzheimer\u2019s disease therapies<\/strong>.<\/p>\n\n\n\n<p>As the <strong>Alzheimer\u2019s disease drug market<\/strong> advances, this trial requires <strong>plasma pTau217 levels<\/strong> consistent with <strong>amyloid pathology<\/strong>, ensuring targeted enrollment of individuals with <strong>minimal cognitive or functional impairment<\/strong>. The study includes <strong>amyloid and tau PET substudies<\/strong> and an <strong>open-label extension<\/strong>, with <strong>completion expected in 2029<\/strong>. <strong>Remternetug<\/strong> has already demonstrated <strong>significant amyloid plaque reduction<\/strong> in early-stage trials, with no <strong>treatment-emergent anti-drug antibodies detected<\/strong>. As it progresses through <strong>Phase III trials<\/strong>, <strong>Remternetug<\/strong> stands as a promising <strong>disease-modifying therapy<\/strong>, potentially transforming the <strong>Alzheimer\u2019s disease treatment landscape<\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-efficacy-and-safety-profile\"><span class=\"ez-toc-section\" id=\"Efficacy_and_Safety_Profile\"><\/span>Efficacy and Safety Profile<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The <strong>TRAILRUNNER-ALZ1<\/strong> study, launched in <strong>August 2022<\/strong>, is a<strong> clinical trial<\/strong> designed to evaluate the <strong>efficacy and safety<\/strong> of <strong>Remternetug (LY3372993)<\/strong> in individuals with <strong>early Alzheimer&#8217;s disease<\/strong>. The study aims to enroll <strong>1,667 participants<\/strong> aged <strong>60\u201385 years<\/strong>, with the trial expected to run until <strong>March 2026<\/strong>. Participants may receive either <strong>Remternetug<\/strong> or a <strong>placebo<\/strong>, with a treatment duration of up to <strong>two years<\/strong>. The trial primarily assesses <strong>amyloid plaque clearance<\/strong>, along with <strong>safety measures<\/strong>, including monitoring for adverse events and the presence of <strong>anti-drug antibodies<\/strong>.<\/p>\n\n\n\n<p>Building on this, the <strong>TRAILRUNNER-ALZ3 study<\/strong>, initiated in <strong>October 2024<\/strong>, focuses exclusively on the <strong>efficacy of Remternetug<\/strong> in early <strong>Alzheimer\u2019s disease treatment<\/strong>. By targeting <strong>amyloid pathology<\/strong> and evaluating its potential as a <strong>disease-modifying therapy<\/strong>, Remternetug is positioning itself as a promising candidate in the <strong>Alzheimer\u2019s disease drug market<\/strong>. With its ability to <strong>significantly reduce amyloid plaques<\/strong>, ongoing trials will determine if <strong>Remternetug<\/strong> can offer a <strong>safer and more effective alternative<\/strong> in the evolving <strong>Alzheimer\u2019s disease treatment scenario<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-alzheimer-s-disease-current-market-scenario\"><span class=\"ez-toc-section\" id=\"Alzheimers_Disease_Current_Market_Scenario\"><\/span>Alzheimer\u2019s Disease Current Market Scenario<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-pipeline-insight\"><strong>Alzheimer\u2019s disease drug landscape<\/strong><\/a><strong> <\/strong>has long been dominated by <strong>symptom-modifying treatments<\/strong>, primarily targeting <strong>neurotransmitter regulation<\/strong> through acetylcholinesterase inhibitors (AChEIs) like <strong>donepezil, rivastigmine, and galantamine<\/strong>, as well as <strong>memantine<\/strong>, an <strong>NMDA receptor antagonist<\/strong>. While these medications provide <strong>temporary cognitive benefits<\/strong>, they fail to <strong>halt disease progression<\/strong>, necessitating frequent reassessment of treatment efficacy. Additionally, <strong>side effects and varying benefit-risk ratios<\/strong> have led to <strong>inconsistent reimbursement policies<\/strong> across different regions, limiting accessibility for some patients.<\/p>\n\n\n\n<p>However, this landscape is undergoing a <strong>transformational shift<\/strong>. The <strong>recent FDA approvals<\/strong> of <strong>LEQEMBI, KISUNLA, and REXULTI <\/strong>mark a growing focus on <strong>disease-modifying therapies (DMTs)<\/strong> aimed at <strong>reducing amyloid plaques<\/strong> rather than simply managing symptoms. These advancements signal a move toward <strong>more personalized and targeted treatment strategies<\/strong>, fueling both <strong>market expansion<\/strong> and <strong>investment in next-generation therapies<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-how-remternetug-stands-out-in-the-current-alzheimer-s-therapeutic-landscape\"><span class=\"ez-toc-section\" id=\"How_Remternetug_Stands_Out_in_the_Current_Alzheimers_Therapeutic_Landscape\"><\/span>How Remternetug Stands Out in the Current Alzheimer\u2019s Therapeutic Landscape<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Amid this evolving treatment paradigm, <strong>Remternetug<\/strong> emerges as a <strong>strong contender in the Alzheimer\u2019s disease drug market<\/strong>. As the successor to Donanemab, <strong>Remternetug<\/strong> represents a major breakthrough in the evolving <a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-market\"><strong>Alzheimer\u2019s disease treatment scenario<\/strong><\/a>. Among emerging <strong>Alzheimer\u2019s disease drugs<\/strong>, it stands out due to its ability to rapidly and effectively clear amyloid plaques, a key pathological feature of the disease. Phase I clinical trials demonstrated a strong dose-dependent response, with higher doses (700\u20132800 mg) leading to significant reductions in amyloid burden. By day 169, 18 out of 24 treated patients achieved amyloid clearance, underscoring its potential as a game-changing therapy in the <strong>Alzheimer\u2019s disease treatment<\/strong> landscape.<\/p>\n\n\n\n<p>With its <strong>Phase III trial<\/strong> expected to conclude by <strong>October 2025, Remternetug<\/strong> is positioned to redefine <strong>Alzheimer\u2019s disease therapies<\/strong>. Its ability to deliver rapid and sustained amyloid clearance could make it one of the most effective <strong>Alzheimer\u2019s disease drugs<\/strong> available. If successful, it may offer a more efficient and targeted approach compared to existing monoclonal antibodies, further strengthening its role in the next generation of <strong>treatment<\/strong> options for Alzheimer\u2019s disease.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-the-future-of-alzheimer-s-treatment-a-step-closer-to-a-breakthrough\"><span class=\"ez-toc-section\" id=\"The_Future_of_Alzheimers_Treatment_A_Step_Closer_to_a_Breakthrough\"><\/span>The Future of Alzheimer\u2019s Treatment: A Step Closer to a Breakthrough<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>With decades of research and countless setbacks, the <strong><em>fight against Alzheimer\u2019s<\/em><\/strong> has been defined by perseverance and incremental progress. However, the emergence of disease-modifying therapies signals a new era\u2014one that goes beyond symptom management to target the underlying pathology. <strong>Remternetug<\/strong>, with its robust amyloid-clearing potential and promising clinical data, stands at the forefront of this revolution. If its Phase III trials confirm its efficacy and safety, it could redefine the treatment paradigm, offering patients and caregivers a tangible step toward slowing disease progression. As the Alzheimer\u2019s disease landscape evolves, Remternetug has the potential to not only be a breakthrough therapy but a beacon of hope in the ongoing battle against neurodegeneration.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12124206\/Alzheimers-Disease-Market-Outlook-1024x194.png\" alt=\"Alzheimer's Disease Market Outlook\" class=\"wp-image-31013\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12124206\/Alzheimers-Disease-Market-Outlook-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12124206\/Alzheimers-Disease-Market-Outlook-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12124206\/Alzheimers-Disease-Market-Outlook-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12124206\/Alzheimers-Disease-Market-Outlook-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12124206\/Alzheimers-Disease-Market-Outlook-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/12124206\/Alzheimers-Disease-Market-Outlook.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Alzheimer\u2019s disease has become one of the most pressing global health challenges, with its prevalence rising dramatically over the past few years. As the aging population grows, so does the burden of this neurodegenerative disorder, placing immense strain on healthcare systems worldwide. The Alzheimer&#8217;s drug market has expanded significantly, driven by the urgent need for [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":31039,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[7145,6642,72,13307,20372,17826,22445,22446],"industry":[17225],"therapeutic_areas":[17229,17245],"class_list":["post-9556","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-alzheimers-disease-market","tag-alzheimers-disease-pipeline","tag-alzheimers-disease","tag-alzheimers-disease-prevalence","tag-alzheimers-disease-treatment","tag-eli-lilly-and-company","tag-ly3372993","tag-remternetug","industry-pharmaceutical","therapeutic_areas-central-nervous-system","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Alzheimer\u2019s Disease Market Outlook and Trends<\/title>\n<meta name=\"description\" content=\"Remternetug, an Eli Lilly therapy targeting amyloid plaques, shows promise as a disease-modifying Alzheimer&#039;s treatment in Phase III trials.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alzheimer\u2019s Disease Market Outlook and Trends\" \/>\n<meta property=\"og:description\" content=\"Remternetug, an Eli Lilly therapy targeting amyloid plaques, shows promise as a disease-modifying Alzheimer&#039;s treatment in Phase III trials.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-12T09:02:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-12T09:09:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/12143347\/Can-Remternetug-Solve-the-Puzzle-of-Alzheimers.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Jatin Vimal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jatin Vimal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Alzheimer\u2019s Disease Market Outlook and Trends","description":"Remternetug, an Eli Lilly therapy targeting amyloid plaques, shows promise as a disease-modifying Alzheimer's treatment in Phase III trials.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market","og_locale":"en_US","og_type":"article","og_title":"Alzheimer\u2019s Disease Market Outlook and Trends","og_description":"Remternetug, an Eli Lilly therapy targeting amyloid plaques, shows promise as a disease-modifying Alzheimer's treatment in Phase III trials.","og_url":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-02-12T09:02:55+00:00","article_modified_time":"2025-02-12T09:09:36+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/12143347\/Can-Remternetug-Solve-the-Puzzle-of-Alzheimers.png","type":"image\/png"}],"author":"Jatin Vimal","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Jatin Vimal","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market","url":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market","name":"Alzheimer\u2019s Disease Market Outlook and Trends","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/12143347\/Can-Remternetug-Solve-the-Puzzle-of-Alzheimers.png","datePublished":"2025-02-12T09:02:55+00:00","dateModified":"2025-02-12T09:09:36+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158"},"description":"Remternetug, an Eli Lilly therapy targeting amyloid plaques, shows promise as a disease-modifying Alzheimer's treatment in Phase III trials.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/alzheimers-disease-market#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/12143347\/Can-Remternetug-Solve-the-Puzzle-of-Alzheimers.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/12143347\/Can-Remternetug-Solve-the-Puzzle-of-Alzheimers.png","width":466,"height":284,"caption":"Can Remternetug Solve the Puzzle of Alzheimer\u2019s"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/c846f0323e948c55336d657b654f3158","name":"Jatin Vimal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/10dcf4b5071c366691525fa20af33b87e8a3897e6d0acc1a2b09a7b99b8d8ae1?s=96&d=mm&r=g","caption":"Jatin Vimal"},"sameAs":["https:\/\/www.delveinsight.com"]}]}},"author_meta":{"display_name":"Jatin Vimal","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/jatin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/02\/12143347\/Can-Remternetug-Solve-the-Puzzle-of-Alzheimers-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Alzheimer&#039;s Disease Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Alzheimer&#039;s disease pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Alzheimer\u2019s disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Alzheimer\u2019s Disease Prevalence<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Alzheimer\u2019s Disease Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Eli Lilly and Company<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">LY3372993<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Remternetug<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Alzheimer&#039;s Disease Market<\/span>","<span class=\"advgb-post-tax-term\">Alzheimer&#039;s disease pipeline<\/span>","<span class=\"advgb-post-tax-term\">Alzheimer\u2019s disease<\/span>","<span class=\"advgb-post-tax-term\">Alzheimer\u2019s Disease Prevalence<\/span>","<span class=\"advgb-post-tax-term\">Alzheimer\u2019s Disease Treatment<\/span>","<span class=\"advgb-post-tax-term\">Eli Lilly and Company<\/span>","<span class=\"advgb-post-tax-term\">LY3372993<\/span>","<span class=\"advgb-post-tax-term\">Remternetug<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Feb 12, 2025","modified":"Updated on Feb 12, 2025"},"absolute_dates_time":{"created":"Posted on Feb 12, 2025 2:32 pm","modified":"Updated on Feb 12, 2025 2:39 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9556","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=9556"}],"version-history":[{"count":2,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9556\/revisions"}],"predecessor-version":[{"id":31041,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9556\/revisions\/31041"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/31039"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=9556"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=9556"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=9556"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=9556"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=9556"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}